205 related articles for article (PubMed ID: 27678429)
1. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
Béliard S; Millier A; Carreau V; Carrié A; Moulin P; Fredenrich A; Farnier M; Luc G; Rosenbaum D; Toumi M; Bruckert E;
J Clin Lipidol; 2016; 10(5):1129-1136.e3. PubMed ID: 27678429
[TBL] [Abstract][Full Text] [Related]
2. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
[TBL] [Abstract][Full Text] [Related]
4. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects.
Béliard S; Carreau V; Carrié A; Giral P; Duchêne E; Farnier M; Ferrières J; Fredenrich A; Krempf M; Luc G; Moulin P; Bruckert E
Atherosclerosis; 2014 May; 234(1):136-41. PubMed ID: 24637413
[TBL] [Abstract][Full Text] [Related]
5. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
[TBL] [Abstract][Full Text] [Related]
8. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
9. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
10. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
11. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.
Brunham LR; Cermakova L; Lee T; Priecelova I; Alloul K; de Chantal M; Francis GA; Frohlich J
Can J Cardiol; 2017 Mar; 33(3):385-392. PubMed ID: 27931859
[TBL] [Abstract][Full Text] [Related]
13. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
[TBL] [Abstract][Full Text] [Related]
14. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
[TBL] [Abstract][Full Text] [Related]
15. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
16. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
17. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
18. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
19. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
